Welcome to our dedicated page for Skye Bioscience SEC filings (Ticker: SKYE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Skye Bioscience, Inc. (Nasdaq: SKYE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Skye is a Nevada corporation and clinical-stage biotechnology company focused on metabolic health, and its filings offer structured insight into its financial condition, clinical programs, and material corporate events.
Investors researching SKYE can use this page to review current and historical reports such as Form 8-K, where Skye has furnished press releases on topics including topline CBeyond™ Phase 2a data for nimacimab, financial results for specific reporting periods, and other corporate updates. These 8-K filings link clinical milestones—such as Phase 2a obesity trial readouts, extension study enrollment, and Phase 1b results in metabolic-associated steatotic liver disease—to the company’s formal disclosure record.
Through Stock Titan, Skye’s filings are updated in near real time as they appear on the SEC’s EDGAR system. AI-powered summaries help explain the key points in lengthy documents, allowing users to quickly understand the context of complex clinical and financial information. This includes highlighting how Skye describes nimacimab’s development status, safety and efficacy data reported in furnished press releases, and the company’s stated plans for future clinical studies.
In addition to event-driven Form 8-Ks, users can locate Skye’s annual and quarterly reports, once available, to examine consolidated financial statements, research and development expenditures, and risk factor discussions related to its obesity and metabolic health programs. The filings page also provides a path to monitor any future ownership and insider transaction disclosures, such as Form 4 filings, when they are reported. Together, these documents form a detailed regulatory history that supports deeper analysis of SKYE as a clinical-stage biotech issuer.
Skye Bioscience furnished an update on its business and reported financial results for the period ended September 30, 2025 via a press release attached to a Form 8-K.
The company submitted the press release as Exhibit 99.1 under Item 2.02. Consistent with General Instruction B.2, this information is furnished and not deemed filed under the Exchange Act.
Skye Bioscience (SKYE) filed its Q3 2025 10‑Q, reporting wider losses as it advances obesity drug development. The company posted a net loss of $12,754,660 for the quarter. Operating expenses rose to $13,264,534, driven by research and development of $9,357,444 and general and administrative costs of $3,907,090.
Liquidity remained solid for near‑term plans: cash and cash equivalents were $18,441,079 and short‑term investments were $16,871,229, totaling $35,312,308 as of September 30, 2025. Total stockholders’ equity was $32,836,185. As of November 7, 2025, 32,057,461 shares were outstanding.
In its CBeyond Phase 2a study, nimacimab monotherapy did not meet the primary endpoint for weight loss versus placebo. However, the combination of nimacimab 200 mg with semaglutide showed greater weight loss than semaglutide alone at 26 weeks and maintained a favorable safety profile. The 26‑week extension enrolled 43 patients, with data expected in Q1 2026.
Skye Bioscience, Inc. (SKYE) announced it will host a conference call and live webcast to discuss a material event on
Insider sales by a director/10% owner over two days. Andrew J. Schwab, reporting as a director and a 10% owner through affiliated 5AM entities, reported multiple open-market dispositions of Skye Bioscience (SKYE) common stock on 08/21/2025 and 08/22/2025. The filings show weighted-average sale prices in two ranges: $3.55–$3.69 for 08/21 and $3.30–$3.59 for 08/22. Reported individual dispositions total 58,642; 2,314; 163,979; and 6,470 shares across the two days, with ownership reported on various lines as indirect through 5AM Ventures II, 5AM Co-Investors II, and 5AM Ventures VII. The form is signed by Mr. Schwab on 08/22/2025.
Skye Bioscience insiders reported multiple sales of common stock on August 21-22, 2025. Entities affiliated with 5AM sold a total of 231,405 shares across two days at weighted-average prices of $3.57 (sales on 08/21) and $3.42 (sales on 08/22), with transaction prices in footnotes ranging from $3.30 to $3.69. After the reported transactions, the filing shows beneficial ownership positions including 1,621,043, 63,963, 1,457,064, 57,493 and a block of 8,167,206 shares held indirectly by 5AM-affiliated entities. The report is signed by the applicable 5AM entities and individual managing members.
Schonfeld Strategic Advisors LLC filed an amendment to a Schedule 13G reporting ownership of 1,115,939 shares of Skye Bioscience, Inc. common stock, representing 3.60% of the class. The filing states those shares are held for the ordinary course of business and not for the purpose of influencing control. Schonfeld reports sole voting and dispositive power over the reported shares and notes that some shares are held in separately managed accounts for clients who retain the right to dividends or sale proceeds.
FAQ
What is the current stock price of Skye Bioscience (SKYE)?
What is the market cap of Skye Bioscience (SKYE)?
